Sardocor

Focus: Sardocor is a Boston-based gene therapy biotech founded in 2019, focused on developing AAV-based therapies for heart failure and related cardiomyopathies. The company is in early-stage clinical development with a focused pipeline targeting significant unmet needs in cardiac disease.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About Sardocor

AI assessmentNot Hiring

No open roles listed right now. Follow Sardocor to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SRD-001

DMD-Associated Dilated Cardiomyopathy

Phase 1

Clinical Trials (1)

NCT06224660Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Phase 1

Help build intelligence for Sardocor

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a gene therapy pioneer at the frontier of cardiac regeneration with a focused, manageable pipeline in early clinical stages
Opportunity to shape a company's trajectory from inception—founded in 2019, still building core capabilities in a high-value therapeutic area
Leverage Boston's biotech ecosystem and proximity to leading academic cardiac programs for research and recruitment synergies

Watch Out For

Zero active job postings currently; hiring velocity and near-term expansion plans are unclear
All programs in Phase 1/2 with no Phase 3 data yet—clinical success remains unproven and regulatory pathway uncertain
No public financial data available; funding status and cash runway are undisclosed, creating risk visibility gaps

Generated by Claude from Sardocor's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AAV1/SERCA2a

Heart Failure, Diastolic

Phase 1

Clinical Trials (1)

NCT06061549Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

Phase 1

SRD-001

Congestive Heart Failure

Phase 1/2

Clinical Trials (1)

NCT04703842Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 3 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

3 pipeline

Marketed

Pipeline